MA44781B1 - Composé hétérocyclique condensé - Google Patents

Composé hétérocyclique condensé

Info

Publication number
MA44781B1
MA44781B1 MA44781A MA44781A MA44781B1 MA 44781 B1 MA44781 B1 MA 44781B1 MA 44781 A MA44781 A MA 44781A MA 44781 A MA44781 A MA 44781A MA 44781 B1 MA44781 B1 MA 44781B1
Authority
MA
Morocco
Prior art keywords
heterocyclic compound
fused heterocyclic
fused
salt
disclosed
Prior art date
Application number
MA44781A
Other languages
English (en)
Other versions
MA44781A (fr
Inventor
Youichi Kawakita
Takuto Kojima
Noriyuki Nii
Yoshiteru Ito
Nobuki Sakauchi
Hiroshi Banno
Xin Liu
Koji Ono
Keisuke Imamura
Shinichi Imamura
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA44781A publication Critical patent/MA44781A/fr
Publication of MA44781B1 publication Critical patent/MA44781B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un composé représenté par la formule suivante, ou un sel de celui-ci
MA44781A 2016-04-28 2017-04-27 Composé hétérocyclique condensé MA44781B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016091717 2016-04-28
PCT/JP2017/016717 WO2017188374A1 (fr) 2016-04-28 2017-04-27 Composé hétérocyclique condensé

Publications (2)

Publication Number Publication Date
MA44781A MA44781A (fr) 2019-03-06
MA44781B1 true MA44781B1 (fr) 2022-10-31

Family

ID=60159711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44781A MA44781B1 (fr) 2016-04-28 2017-04-27 Composé hétérocyclique condensé

Country Status (20)

Country Link
US (3) US10577382B2 (fr)
EP (1) EP3450436B1 (fr)
JP (2) JP6924182B2 (fr)
KR (1) KR102431405B1 (fr)
CN (1) CN109415384B (fr)
BR (1) BR112018072039B1 (fr)
CA (1) CA3021185C (fr)
DK (1) DK3450436T3 (fr)
EA (1) EA039529B1 (fr)
ES (1) ES2927529T3 (fr)
HR (1) HRP20221277T1 (fr)
HU (1) HUE059954T2 (fr)
LT (1) LT3450436T (fr)
MA (1) MA44781B1 (fr)
PL (1) PL3450436T3 (fr)
PT (1) PT3450436T (fr)
RS (1) RS63656B1 (fr)
SG (2) SG11201809243YA (fr)
SM (1) SMT202200424T1 (fr)
WO (1) WO2017188374A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109415384B (zh) * 2016-04-28 2022-01-11 武田药品工业株式会社 稠合杂环化合物
CA3195150A1 (fr) 2020-10-08 2022-04-14 Sven Weiler Derives de benzo[h]quinazolin-4-amine et de thieno[3,2-h]quinazolin-4-amine pour le traitement du cancer
CN113773247A (zh) * 2021-07-23 2021-12-10 无锡海伦生物科技有限公司 一种2-氨基-5-碘吡啶的制备方法
JPWO2023190967A1 (fr) * 2022-03-31 2023-10-05
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法
WO2025078334A1 (fr) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combinaison d'inhibiteurs de pak1 et d'inhibiteurs de clk pour prévenir la résistance à la chimiothérapie chez des patients souffrant de leucémie myéloïde aiguë
CN122535406A (zh) 2024-01-12 2026-08-07 日商科迪亚制药股份有限公司 包含clk抑制剂作为有效成分的癌症治疗剂
WO2025256640A1 (fr) * 2024-06-14 2025-12-18 北京康辰药业股份有限公司 Composé macrocyclique, composition pharmaceutique à base de celui-ci et utilisation associée

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144977A0 (en) * 1999-05-21 2002-06-30 Bristol Myers Squibb Co Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
DK2308877T3 (da) * 2008-08-05 2014-04-22 Daiichi Sankyo Co Ltd Imidazopyridin-2-on-derivater
BR112012002942A2 (pt) * 2009-08-10 2015-10-13 Epitherix Llc indazóis como inibidores da trilha de sinalização de wnt/b-catenina e empregos terapêuticos destes.
ES2835553T3 (es) * 2009-08-10 2021-06-22 Biosplice Therapeutics Inc Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
CA2803448A1 (fr) 2010-07-06 2012-01-12 Universite De Montreal Derives d'imidazopyridine, d'imidazopyrimidine et d'imidazopyrazine en tant que modulateurs des recepteurs de melanocortine-4
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN109415384B (zh) * 2016-04-28 2022-01-11 武田药品工业株式会社 稠合杂环化合物

Also Published As

Publication number Publication date
BR112018072039B1 (pt) 2023-12-26
US20190106437A1 (en) 2019-04-11
US11390634B2 (en) 2022-07-19
MA44781A (fr) 2019-03-06
CN109415384A (zh) 2019-03-01
ES2927529T3 (es) 2022-11-08
JP2021176901A (ja) 2021-11-11
JP7130098B2 (ja) 2022-09-02
EP3450436A1 (fr) 2019-03-06
JPWO2017188374A1 (ja) 2019-02-28
WO2017188374A1 (fr) 2017-11-02
US10981934B2 (en) 2021-04-20
US20200140462A1 (en) 2020-05-07
SMT202200424T1 (it) 2022-11-18
EP3450436B1 (fr) 2022-07-27
EA201892449A1 (ru) 2019-05-31
PL3450436T3 (pl) 2022-12-27
CA3021185A1 (fr) 2017-11-02
RS63656B1 (sr) 2022-11-30
CN109415384B (zh) 2022-01-11
KR20190002547A (ko) 2019-01-08
SG11201809243YA (en) 2018-11-29
CA3021185C (fr) 2024-06-04
US20210115067A1 (en) 2021-04-22
EP3450436A4 (fr) 2019-10-30
LT3450436T (lt) 2022-09-12
KR102431405B1 (ko) 2022-08-10
HUE059954T2 (hu) 2023-01-28
SG10201912270PA (en) 2020-02-27
HRP20221277T1 (hr) 2022-12-23
EA039529B1 (ru) 2022-02-07
BR112018072039A2 (pt) 2019-02-12
US10577382B2 (en) 2020-03-03
JP6924182B2 (ja) 2021-08-25
PT3450436T (pt) 2022-09-29
DK3450436T3 (da) 2022-09-12

Similar Documents

Publication Publication Date Title
PH12020500673A1 (en) Compounds
EP3871673A4 (fr) Nouveau composé d'indazole ou sel de celui-ci
BR112017006253A2 (pt) novos compostos
MX374439B (es) Compuesto de piridona como inhibidor de c-met
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
EP3697787A4 (fr) Composé hétérocyclique à utiliser en tant qu'inhibiteur de protéine kinase
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
AR099400A1 (es) Compuesto heterocíclico fusionado
MA40302B1 (fr) Dérivés de carbazole
EP3822276A4 (fr) Composé hétérocyclique utilisé en tant qu'inhibiteur de trk
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
EA201892449A1 (ru) Конденсированные гетероциклические соединения
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201890156A1 (ru) Антагонисты рецептора cgrp
EP3909584A4 (fr) Composé pyrimidine ou sel correspondant
EP3808747A4 (fr) Composé d'imidazopyridinone
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
JOP20200030B1 (ar) مركب خماسي الحلقة
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
EP3856188A4 (fr) Composé d'aminopyrimidine
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative
EP4010323C0 (fr) Dérivés de 2-phénoxy-pyrimidine en tant que composés herbicides
EA201791596A1 (ru) Пиразоловые соединения
EA201992439A2 (ru) Конденсированные гетероциклические соединения и пестициды
MA42602B1 (fr) Antagonistes du recepteur cgrp